Enhancement of the TCRζ expression, polyclonal expansion, and activation of t cells from patients with acute myeloid leukemia after IL-2, IL-7, and IL-12 induction.

PubWeight™: 0.88‹?›

🔗 View Article (PMID 25757160)

Published in DNA Cell Biol on March 10, 2015

Authors

Li Shi1, Shaohua Chen1, Xianfeng Zha2, Yan Xu1,3, Ling Xu1, Lijian Yang1, Yuhong Lu4, Kanger Zhu4, Yangqiu Li1,3

Author Affiliations

1: 1 Institute of Hematology, Jinan University , Guangzhou, China .
2: 2 Department of Clinical Laboratory, First Affiliated Hospital, Jinan University , Guangzhou, China .
3: 3 Key Laboratory for Regenerative Medicine of Ministry of Education, Jinan University , Guangzhou, China .
4: 4 Department of Hematology, First Affiliated Hospital, Jinan University , Guangzhou, China .

Articles cited by this

Interleukin-7: from bench to clinic. Blood (2002) 3.01

The T cell receptor: critical role of the membrane environment in receptor assembly and function. Annu Rev Immunol (2005) 1.64

Chimeric antigen receptor-engineered T cells for cancer immunotherapy: progress and challenges. J Hematol Oncol (2013) 1.46

Reconstitution of deficient T cell receptor zeta chain restores T cell signaling and augments T cell receptor/CD3-induced interleukin-2 production in patients with systemic lupus erythematosus. Arthritis Rheum (2003) 1.38

The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies. J Hematol Oncol (2013) 1.33

Leukemia-associated antigens are critical for the proliferation of acute myeloid leukemia cells. Clin Cancer Res (2008) 1.32

Impaired expression of the CD3-zeta chain in peripheral blood T cells of patients with chronic myeloid leukaemia results in an increased susceptibility to apoptosis. Br J Haematol (2000) 1.05

Deficiency of CD3gamma, delta, epsilon, and zeta expression in T cells from AML patients. Hematology (2011) 1.05

Upregulated TCRζ enhances interleukin-2 production in T-cells from patients with CML. DNA Cell Biol (2012) 0.99

Prognostic factors in elderly patients with AML and the implications for treatment. Hematology Am Soc Hematol Educ Program (2007) 0.99

Alterations in the expression pattern of TCR zeta chain in T cells from patients with hematological diseases. Hematology (2008) 0.98

Oligoclonal TCRBV gene usage in B-cell chronic lymphocytic leukemia: major perturbations are preferentially seen within the CD4 T-cell subset. Blood (1999) 0.98

Alternative expression of TCRζ related genes in patients with chronic myeloid leukemia. J Hematol Oncol (2012) 0.97

Interleukin 7 promotes long-term in vitro growth of antitumor cytotoxic T lymphocytes with immunotherapeutic efficacy in vivo. J Exp Med (1994) 0.94

CD3 deficiencies. Curr Opin Allergy Clin Immunol (2005) 0.93

TRAV and TRBV repertoire, clonality and the proliferative history of umbilical cord blood T-cells. Transpl Immunol (2007) 0.93

The TCR Vbeta repertoire usage of T-cells from cord blood induced by chronic myelogenous leukemia associated antigen. Hematology (2005) 0.92

TCR zeta chain expression in T cells from patients with CML. Hematology (2009) 0.91

The evolution of malignant and reactive γδ + T cell clones in a relapse T-ALL case after allogeneic stem cell transplantation. Mol Cancer (2013) 0.91

Reduced levels of recent thymic emigrants in acute myeloid leukemia patients. Cancer Immunol Immunother (2008) 0.90

Interleukin-12 augments cytolytic activity of peripheral blood lymphocytes from patients with hematologic and solid malignancies. Blood (1993) 0.90

Proliferation inhibition and apoptosis induction of imatinib-resistant chronic myeloid leukemia cells via PPP2R5C down-regulation. J Hematol Oncol (2013) 0.88

Expression feature of CD3, FcεRIγ, and Zap-70 in patients with chronic lymphocytic leukemia. Hematology (2012) 0.86

Characterization of the CDR3 structure of the Vβ21 T cell clone in patients with P210(BCR-ABL)-positive chronic myeloid leukemia and B-cell acute lymphoblastic leukemia. Hum Immunol (2011) 0.86

Immune response as a possible mechanism of long-lasting disease control in spontaneous remission of MLL/AF9-positive acute myeloid leukemia. Ann Hematol (2011) 0.85

Emerging strategies for high-risk and relapsed/refractory acute myeloid leukemia: novel agents and approaches currently in clinical trials. Blood Rev (2014) 0.84

Enhancement of the interferon gamma assay to detect paratuberculosis using interleukin-7 and interleukin-12 potentiation. Vet Immunol Immunopathol (2012) 0.83

The role of the immunosuppressive microenvironment in acute myeloid leukemia development and treatment. Expert Rev Hematol (2014) 0.83

Interaction with mesenchymal stem cells provokes natural killer cells for enhanced IL-12/IL-18-induced interferon-gamma secretion. Mediators Inflamm (2014) 0.82

Clonal expanded TCR Vbeta T cells in patients with APL. Hematology (2005) 0.82

Distribution and clonality of the vα and vβ T-cell receptor repertoire of regulatory T cells in leukemia patients with and without graft versus host disease. DNA Cell Biol (2014) 0.80

The T-cell receptor Vbeta gene repertoire and clonal expansion from peripheral blood T cells in benzene-exposed workers in China. Hematology (2009) 0.79

Lead poisoning influences TCR-related gene expression patterns in peripheral blood T-lymphocytes of exposed workers. J Immunotoxicol (2014) 0.78

Gene expression profiling of CD3gamma, delta, epsilon, and zeta chains in CD4(+) and CD8(+) T cells from human umbilical cord blood. Hematology (2010) 0.76